echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovent's GLP-1R/GCGR dual agonist treatment of type 2 diabetes phase Ib clinical results announced

    Innovent's GLP-1R/GCGR dual agonist treatment of type 2 diabetes phase Ib clinical results announced

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On December 7, Innovent announced that the glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR) dual agonist IBI362 ( LY3305677) multiple-dose, dose-escalated phase Ib clinical study in Chinese type 2 diabetes patients was accepted by the 2021 International Diabetes Federation Conference (IDF 2021) as a conference abstract and published in the form of an online poster

    The study is a randomized, double-blind, placebo-controlled Phase Ib clinical study, which aims to evaluate the safety, tolerability and pharmacokinetics of IBI362 multiple dose escalation administration in Chinese type 2 diabetes patients with poor blood glucose control.
    Pharmacodynamic characteristics, and dulaglycotide was established as an open-label active control group


    The study was divided into 3 cohorts.
    Each cohort enrolled 14 subjects.
    They were randomly assigned to receive IBI362, placebo or 1.
    5 mg dulaglutide at 8:4:2, and were administered by subcutaneous injection once a week for continuous administration.
    12 weeks

    IBI362 or placebo is administered in a dose titration schedule of 1.
    0 mg (cohort 1), 1.
    5 mg (cohort 2) or 2.
    0 mg (cohort 3), at each dose level 4 weeks

    The results of the study showed that IBI362 was well tolerated.
    The most commonly reported adverse events during the treatment period were loss of appetite and gastrointestinal-related adverse events, and most of the events were transient and mild

    At week 12, the mean changes in HbA1c level from baseline of subjects in cohorts 1, 2 and 3 who received IBI362 were −1.
    46%, −2.
    23%, and −1.
    66%, respectively.
    The dulaglutide group was − 1.

    Considering that the variation caused by the limited sample size may have an impact on the results, after excluding the maximum and minimum changes in the level of glycosylated hemoglobin from baseline in each administration group at week 12, cohorts 1, 2 and 3 received IBI362 The adjusted mean values ​​of the changes in glycosylated hemoglobin levels from baseline in the treated subjects were −1.
    46%, −2.
    28%, and −1.
    87%, respectively, and −1.
    46% in the dulaglutide group

    At the same time, the average body weight of subjects treated with IBI362 in cohorts 1, 2, and 3 decreased by 0.
    9%, 5.
    0%, and 5.
    4% from baseline at week 12, and the dulaglutide group decreased by 0.

    The waist circumference, body mass index, blood pressure and blood lipids of subjects treated with IBI362 have also been observed to improve to varying degrees, and the overall trend is similar to that of the IBI362 1b weight loss study [1]


    Note: The original text has been deleted

    Reference materials:

    [1] Ji L, Jiang H, An P, et al.
    (2021) IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled , multiple ascending dose phase 1b study.
    EClinicalMedicine 39: 101088.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.